Salix Pharmaceuticals Ltd. volatility and risk adjusted return

Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) reports Q2 EPS of $0.13 versus estimates of $.10. Salix Pharmaceuticals Ltd. reports Q2 revenues of $140.3 million versus estimates of $93.64 million. Salix seecs Q3 loss of $0.13 versus Street ...

(NASDAQ:SLXP) recently announced the US Food and Drug Administration has accepted for Priority Review the Company's efficacy supplement to the New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of ...

Today's BioHealth Business Daily has many new names and less followed companies, but there are some of the larger movers to consider today as well. We are seeing news-related moves in many stocks from BioMarin Pharmaceutical Inc. ...

Xifaxan Boosts Salix Earnings

Small Caps vs Large Caps-Where to Invest Now

Lightning Round: Boeing, Cadbury, Fifth Third Bancorp and More